גלאסיה - Glassia

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

B02AB
Proteinase inhibitors

××¨××× ×¤×¢×× (ATC5)

Alpha-1-antitrypsin ( aat) 1G / 50 ML âB02AB02

×¦××¨×ª ××ª×

×ª××-××¨××× - I.V

×¦××¨×ª ××× ××

×ª×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Alpha1-Proteinase Inhibitor (Human), GLASSIAÂ® is indicated for chronic augmentation and maintenance therapy in individuals with congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

03/02/2022

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
×. ××××¤×× ××ª×¨××¤× ××× ×ª× ××××¤×× ××××× ××¦×× ××¨×× × ××××¤×× ××××§× ×××××× ×¢× ××¡×¨ ×××× ×-alpha 1 proteinase inhibitor (Alpha 1-antitrypsin deficiency (AAT)) ×¢× ×¢×××ª ×§××× ××ª ×× ×¤××ª ××¨××××ª (Emphysema) ××©×¨ ×¢×× ×× ×¢× ×× ×××: 1. ××¡×¨ ××× ××× (AATD) ××¨×× ××ª××ª ×-11 ÂµM; 2. FEV1 × ××× ×-80%; 3. ××× ××××: ×. ××××× ×¢× ××××¦×× ×©××××× × ×××××§× ×× ×××ª ××¡×× ZZ ×× Null Z, ×× ×¦××¨××£ ×××¨ ×©× ×©×ª× ××××¦×××ª ×××§× ××ª ××¡×¨ ××××¨; ×. ××××× ×××¨×××××××××. ×. ××××¤×× ××ª×¨××¤× ××¢×©× ×¢× ×¤× ××¨×©× ×©× ×¨××¤× ××××× ××¨×¤×××ª ×¨××××ª.	03/02/2022	×¨×¤×××ª ×¨××××ª		Alpha 1-antitrypsin deficiency (AAT)

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

×. ××××¤×× ××ª×¨××¤× ××× ×ª× ××××¤×× ××××× ××¦×× ××¨×× × ××××¤×× ××××§× ×××××× ×¢× ××¡×¨ ×××× ×-alpha 1 proteinase inhibitor (Alpha 1-antitrypsin deficiency (AAT)) ×¢× ×¢×××ª ×§××× ××ª ×× ×¤××ª ××¨××××ª (Emphysema) ××©×¨ ×¢×× ×× ×¢× ×× ×××:

1. ××¡×¨ ××× ××× (AATD) ××¨×× ××ª××ª ×-11 ÂµM;

2. FEV1 × ××× ×-80%;

3. ××× ××××:

×. ××××× ×¢× ××××¦×× ×©××××× × ×××××§× ×× ×××ª ××¡×× ZZ ×× Null Z, ×× ×¦××¨××£ ×××¨ ×©× ×©×ª× ××××¦×××ª ×××§× ××ª ××¡×¨ ××××¨;

×. ××××× ×××¨×××××××××.

×. ××××¤×× ××ª×¨××¤× ××¢×©× ×¢× ×¤× ××¨×©× ×©× ×¨××¤× ××××× ××¨×¤×××ª ×¨××××ª.

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 30.09.2023

××××¨× ××¢××× ××¨××¤× 21.07.2014 (××¡×× Microsoft Word)
××××¨× ××¢××× ××¨××¤× 12.05.2013 (××¡×× Microsoft Word)

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××××¡×× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	KAMADA LTD, ISRAEL
×©× ××¢× ××¨××©××	KAMADA LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 03/2010. ×¨××©××× ××ª××¨××: 07/2016
×ª××¨×× ×¢×××× ×××¨××	14/05/19